We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A novel vehicle for the treatment of psoriasis.
- Authors
Dattola, Annunziata; Silvestri, Martina; Bennardo, Luigi; Passante, Maria; Rizzuto, Francesco; Dastoli, Stefano; Patruno, Cataldo; Bianchi, Luca; Nisticò, Steven Paul
- Abstract
This study evaluates the effectiveness of the topical use of an aerosol foam combination of calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g (Cal/BD foam, Enstilar®) in adults with moderate plaque psoriasis. A total of 120 male and female adult psoriasis patients (53.3% male) from two Italian dermatological units were enrolled in an 8‐week prospective study performed between November 2018 and January 2019. Psoriasis Area and Severity Index (PASI) was evaluated at baseline (T0) and 4 weeks (T4) of daily application, and a further evaluation was carried out 4 weeks after suspension (T8). Furthermore, the Dermatology Life Quality Index (DLQI) was evaluated at baseline and after 4 weeks of treatment (T4). At baseline, patients presented a mean PASI of 7 (7.0 ± 2.1). After 4 weeks (T4) of once‐daily application, an important improvement in PASI was observed (1.1 ± 0.3). At Week 4, DLQI was reduced by 5.5 points from baseline (mean: 12 ± 3.1 at T0 vs 6.5 ± 1.8 at T4). Four weeks after suspension (T8), mean PASI was 2.6 ± 1.9, which was stable compared to the previous evaluation; only 8.3% of the treated patients showed worsening of plaque psoriasis. This study suggested that the Cal/BD aerosol foam is an effective topical therapy to treat plaque psoriasis.
- Subjects
PSORIASIS; QUALITY of life; AEROSOLS; FOAM
- Publication
Dermatologic Therapy, 2020, Vol 33, Issue 1, pN.PAG
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.13185